A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Part of paid clinical trials in Bethesda, Maryland.

Sponsor
National Cancer Institute (NCI)
Study ID
NCT02821754
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Durvalumab — DRUG
    Flat dose of 1500 mg every 4 weeks.
  • Tremelimumab — DRUG
    Flat dose of 75 mg every 4 weeks for up to 4 doses.
  • Trans-arterial Catheter Chemoembolization (TACE) — PROCEDURE
    TACE will be performed on Day 36 (+/-96hrs).
  • Radiofrequency Ablation (RFA) — PROCEDURE
    RFA will be performed on Day 36 (+/-96hrs).
  • Cryoablation — PROCEDURE
    Cryoablation will be performed on Day 36 (+/-96hrs).

Study Details

BACKGROUND: * Various tumor ablative procedures and techniques have been shown to result in immunogenic cell death and induction of a peripheral immune response. The term ablative therapies applies to trans-arterial catheter chemoembolization (TACE), radiofrequency ablation (RFA) and cryoablation (CA). * The underlying hypothesis of this study is that the effect of immune checkpoint inhibition can be enhanced by TACE, CA and RFA in patients with advanced hepatocellular carcinoma (HCC) and biliary tract carcinomas (BTC). We have already demonstrated proof of principle as well as safety and feasibility of this approach with anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) therapy. * Based on the concept of programmed death-ligand 1 (PDL1)-mediated adaptive resistance and the emerging role of programmed cell death protein 1 (PD1) therapy in HCC, we would like to evaluate the combination of tremelimumab and durvalumab (with ablative therapies) in HCC and BTC. Objectives: \- To preliminarily evaluate the 6-month progression free survival (PFS) of combining tremelimumab and durvalumab in patients with advanced HCC (either alone or with cryoablation, TACE or RFA) and in patients with advanced biliary tract carcinoma (BTC) (either alone or with cryoablation or RFA). ELIGIBILITY: * Histologically or cytologically confirmed diagnosis of HCC or biliary tract carcinoma OR histopathological confirmation of carcinoma in the setting of clinical and radiological characteristics which, together with the pathology, are highly suggestive of a diagnosis of HCC (or biliary tract carcinoma). * Childs-Pugh A/B7 cirrhosis only is allowed. If patient does not have cirrhosis, this limitation does not apply. * Patients must have disease that is not amenable to potentially curative resection, radiofrequency ablation, or liver transplantation. DESIGN: We will evaluate the combination of tremelimumab and durvalumab (with ablative therapies) in cohorts A (HCC; N=40) and B (BTC; N=30). The first N=10 patients in both cohorts will receive tremelimumab and durvalumab only (i.e. No interventional radiologic procedures). * A: Advanced HCC, BCLC# Stage B/C * N= 1st 10 pts: No ablative procedure Cryoablation/RFA/TACE## * Tremelimumab 75mg flat dose every (q)28 days for 4 doses; Durvalumab 1500mg flat dose q28 days until end of study (EOS)### * 40 total: 10 trem+ dur alone; 10 trem+ dur + TACE; 10 trem + dur + RFA; 10 trem + dur + cryo * B: Intra/extra-hepatic cholangiocarcinoma * N= 1st 10 patients (pts): No ablative procedure; RFA/ cryoablation * Tremelimumab 75mg flat dose q28 days for 4 doses; Durvalumab 1500mg flat dose q28 days until EOS### * 30 total: 10 trem+ dur alone; 10 trem + dur + RFA; 10 trem * BCLC = Barcelona clinic liver cancer staging system * For BCLC stage B patients TACE may be repeated as per standard of care * EOS = End of study treatment or meeting any of the off-treatment or off study criteria.

Key Dates

Start date
Jul 5, 2016
Status verified
Mar 2023
Primary completion
Feb 17, 2021
Completion
Dec 31, 2022

Study Design

Enrollment
54 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: 1/A1-Durvalumab + Tremelimumab
    Durvalumab + Tremelimumab
  • Experimental: 2/A2 - Durvalumab + Tremelimumab + Trans-arterial Catheter Chemoembolization (TACE)
    Durvalumab + Tremelimumab + TACE
  • Experimental: 3/A3 - Durvalumab + Tremelimumab+ Radiofrequency Ablation (RFA)
    Durvalumab + Tremelimumab+ RFA
  • Experimental: 4/A4 - Durvalumab + Tremelimumab+ Cryoablation
    Durvalumab + Tremelimumab+ Cryoablation

Primary Outcome Measure

6 Month Progression Free Survival (PFS) [ Time Frame: At 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
National Institutes of Health Clinical CenterBethesdaMaryland20892-

Find similar trials in Bethesda, MD

By condition
Liver cancer
By specialty
OncologyGI oncologyHepatology
By research site
National Institutes of Health Clinical Center· Bethesda, MD

Related Studies